Locally advanced cervical cancer (stage IB3, IIA2) patients with postoperative risk factors need better treatment. We initiated a clinical study to explore the effectiveness of adjuvant chemoradiotherapy followed by Zimberelimab for these patients.
Histologically confirmed cervical squamous cell carcinoma, cervical adenocarcinoma, or cervical adenosquamous carcinoma;
According to FIGO2018 staging, patients with locally advanced cervical cancer (IB3, IIA2) who require concurrent radiotherapy and chemotherapy;
Patients with radical surgery for cervical cancer;
Female patients: 18-70 years old;
Subjects have histological subtypes other than those permitted by inclusion criteria;
Severe hypersensitivity to cepalizumab and/or any of its excipients (≥ grade 3);
Participate in or have participated in other clinical trials within 4 weeks before enrollment;
Have received or will receive inactivated vaccine within 30 days prior to the first study treatment;